European CHMP recommends approval of Carmustine Obvius for use as a conditioning treatment prior to autologous haematopoietic progenitor cell transplantation
The CHMP has issued a positive opinion recommending the approval of this additional indication for Carmustine Obvius, in patients with malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).
Source:
European Medicines Agency